BioCryst Pharmaceuticals Forms Scientific Advisory Board as R&D Model Evolves

MT newswire2026/10/05 12:33

08:33 AM EDT, 10/05/2026 (MT Newswires) -- BioCryst Pharmaceuticals (BCRX) formed a seven-member Scientific Advisory Board to guide its research & development strategy and help expand its rare disease pipeline, the company said Monday. The board will advise on pipeline expansion, external innovation opportunities, translational science, clinical development and regulatory strategy, the company said. BioCryst Pharmaceuticals shares were up 1.4% in premarket activity.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

You may also like

Only 1.45 Billion Shiba Inu (SHIB) Burned in 24 Hours Hints at Reversal

UToday•2026/10/11 10:27

Viral Altcoin Defies Market Slumber With 53% Surge, BTC Calms at $83K: Weekend Watch

Cryptopotato•2026/10/11 10:21

Global Bank Stocks Sink as Bond Losses Top $326 Billion: Is Another SVB Coming?

BeInCrypto•2026/10/11 10:06

Exclusive Report - Sources Say INWIT Investors Are Raising Funds for a Possible Privatization Deal

路透社•2026/10/11 08:51